Opinion|Videos|December 14, 2023
Will Combination Therapies Replace Osimertinib Monotherapy as Standard-of-Care in Frontline EGFR-Mutant Advanced NSCLC?
Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5